Influenza Clinical Trial
— SEA 004Official title:
A Phase IV, Multi-center, Randomized, Partially Double Blinded, Placebo Controlled Study, to Evaluate the Safety of Daily Inhaled Zanamivir 10 mg Versus Placebo and Daily Oral Oseltamivir 75 mg Versus Placebo for Influenza Prophylaxis in Healthy Volunteers for 16 Weeks
This is a multicenter, randomised, four arms placebo controlled study to evaluate the safety
and tolerability of 10 mg inhaled zanamivir once a day and 75 mg oseltamivir capsule orally
once a day relative to placebo over 16 weeks (112 days). Enrolled subjects will be randomly
assigned to 2:1:2:1 ratio (active oseltamivir: placebo: active zanamivir: placebo) on one of
the four study treatment groups.
It is hypothesized that oseltamivir and zanamivir will protect participants from becoming
infected with influenza.
Status | Completed |
Enrollment | 390 |
Est. completion date | September 2010 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 20 Years to 65 Years |
Eligibility |
Inclusion Criteria: - A subject will be eligible for inclusion in this study only if all of the following criteria apply: 1. Healthy male or female aged 20 - 65 years. Healthy determined by the Investigator based on medical history and screening examinations. 2. Read and understand study related materials intended for subject. 3. Signed informed consent prior to study participation. 4. Willingness and ability to comply with the study protocol for the duration of the trial. 5. Female subject who is of reproductive potential agrees to use an acceptable method of birth control (e.g., intrauterine device, abstinence or hormonal contraceptive drug) throughout the study (D120+2). 6. For male subject, he must agree to use an acceptable method of birth control (e.g. abstinence or condom) throughout the study (D120+2). Exclusion Criteria: - A subject will not be eligible for inclusion in this study if any of the following apply: 1. Females who are pregnant, trying to get pregnant or are lactating. 2. Current or a history of asthma or chronic obstructive pulmonary disease within the last 5 years. 3. Abnormal pulmonary function test according to The Thoracic Society of Thailand Guidelines for Pulmonary Function Tests: (i) FVC < 80% of the predicted value for age and sex or (ii) FEV1/FVC <70%. (see Appendix 2) 4. Any other chronic or acute diseases requiring treatment. 5. An abnormal ECG indicating disease that requires immediate investigation or treatment 6. An abnormal chest x-ray indicating an active disease process. 7. A creatinine clearance < 30 mL/min as determined by Cockcroft-Gault equation (see below) 8. AST or ALT = 1.5 x ULN 9. Use of a live attenuated influenza vaccine or any anti-influenza drug within 14 days prior to the first dose of study drugs/placebos. 10. History of alcohol or substance abuse or dependence which in the opinion of the investigator would interfere with subject compliance or safety 11. Subjects who have a history of allergy to the study drug or drugs of the same class, or a history of severe drug (e.g. toxic epidermal necrolysis) or other allergy (e.g. previous history of anaphylaxis) that, in the opinion of the investigator, contraindicates participation in the trial. 12. The subject has participated in a clinical trial and has received investigational drugs within 60 days prior to the first dose of study drug. 13. Subjects who, in the opinion of the investigator, are unlikely to comply fully with study procedures. 14. History of any mental illness requiring hospitalisation or outpatient psychiatric treatment within the last 12 months 15. Any suicidal attempt within the previous 5 years. 16. Screening HADS anxiety or depression score > 8. 17. Hemoglobin <11g/dL or neutropenia of < 1000 per microlitre or a platelet count of less than 100,000 cells/mm3 Cockroft formula: CrCl (mL/min) = (140 - age) x Wt / 72 x serum creatinine (females x 0.85), age in years, Wt in kg, serum creatinine in mg/dL. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Thailand | Faculty of Medicine Siriraj Hospital | Bangkok | Bangkoknoi |
Thailand | Hospital for Tropical Diseases | Bangkok |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | National Institute of Allergy and Infectious Diseases (NIAID) |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects who withdraw from the study because of serious adverse events (SAEs) that are possibly or probably or definitely related to the study drug | 1 year | Yes | |
Secondary | Proportion of subjects who withdraw from the study because of SAEs unlikely or not related to study drug/placebo | 1 year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |